More drama ahead: Sarepta plans to file for accelerated Duchenne approval, with adcomm a 'near certainty' - Endpoints News

While Sarepta has three antisense oligonucleotide therapies approved — albeit not without controversy — for Duchenne muscular dystrophy, it has been working on a long-term treatment in the form of a gene therapy. After posting positive results for its Roche-p…

Most pharma TV commercials include a link at the end of the ad, offering a website link for viewers who want more information. It turns out millions of them do. So far in 2022, AbbVie, Novo Nordisk a… [+606 chars]

full article...